The first patients at UHSussex have now been able to receive a new, innovative cancer therapy for prostate cancer, through a clinical trial, marking an important step forward in cancer care.
In December, the Trust treated its first patients with a new targeted treatment called Lutetium PSMA, as part of the national STAMPEDE 2 trial for people with hormone-sensitive prostate cancer.
Using advanced scans (so called PET-CT PSMA) , clinicians were able to pinpoint cancer cells and deliver internal radiation directly to those, while helping protect surrounding healthy tissue. While offering hope to our prostate cancer patients, this research is a significant step in improving cancer care for patients now, and in the future.
Reaching this milestone for UHSussex would not have been possible without our patients, as well as the outstanding teamwork across cancer, nuclear medicine, medical physics and Research and Innovation teams. Funding from the Sussex Cancer Fund has enabled a new Research Radiographer post to help open more national radiotherapy trials in Sussex, giving local patients access to cutting-edge treatments without having to travel.
Find out more about how research is improving patient care at UHSussex.
Interested in taking part in research? Find out what studies are available at NIHR Be Part of Research.